Johnson & Johnson reported a 5.3% increase in Q4 sales, reaching $22.5 billion. EPS was reported at $1.41 and adjusted EPS at $2.04, which included $(0.22) impact from acquired IPR&D charges related to the V-Wave acquisition. The company issued guidance for 2025, projecting operational sales growth of 2.5% - 3.5% and adjusted operational EPS of $10.75 - $10.95.
Q4 2024 sales increased by 5.3% to $22.5 billion with operational growth of 6.7%.
Q4 2024 EPS was $1.41, and adjusted EPS was $2.04, including a $(0.22) impact from acquired IPR&D charges.
Full-year sales grew by 4.3% to $88.8 billion, with operational growth of 5.9%.
The company is guiding for 2025 with operational sales growth of 2.5% - 3.5% and adjusted operational EPS of $10.75 - $10.95.
Johnson & Johnson issued guidance for 2025, expecting adjusted operational sales growth and adjusted EPS (diluted).
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance